La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma GalleryLa EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma
La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma
El Comité para la designación de medicamentos huérfanos (COMP) de la Agencia Europea del Medicamento (EMA) comunica a la compañía vasca Atlas Molecular Pharma S. L. su opinión favorable a la solicitud del fármaco L2.7.D7 [...]
Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria
DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, [...]
ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)
ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]
Drugs against rare diseases
José María Mato, Óscar Millet and Joaquín Castilla present their research on Porphyria and Prion diseases, and how ATLAS molecular pharma is a clear example of translational biomedical research. Related info: Eitb.eus Radio https://vimeo.com/206707728
A possible pharmacological chaperone for congenital erythropoietic porphyria
The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. [...]
Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th
Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering [...]